LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Sanofi

Sanofi

Suletud

57.74 -0.89

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

57.61

Max

57.79

Põhinäitajad
By Trading Economics
Sissetulek	-20M 1.1B
Müük	262M 11B
P/E Sektori keskmine	25.1 103.001
Aktsiakasum	0.455
Kasumimarginaal	9.78
EBITDA	-136M 2B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+0.47 upside

Turustatistika
By TradingEconomics
Turukapital	142B
Eelmine avamishind	58.63
Eelmine sulgemishind	57.74

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

56.21 / 58.15 Toetus ja vastupanu

Sanofi Graafik

Seotud uudised

25. juuli 2024, 05:44 UTC

Tulu

Sanofi Raises Guidance After Profit, Sales Beat

4. juuli 2024, 06:44 UTC

Omandamised, ülevõtmised, äriostud

Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports

27. juuni 2024, 10:54 UTC

Suurimad hinnamuutused turgudel

Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment

26. juuni 2024, 07:15 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Starts Bidding Process to Sell Consumer Health Division, Bloomberg Reports

13. mai 2024, 18:14 UTC

Suurimad hinnamuutused turgudel

Novavax Shares Pop Another 50% Following Sanofi Deal

25. juuli 2024, 13:20 UTC

Tulu

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

25. juuli 2024, 11:46 UTC

Market Talk

Tulu

Sanofi Aims to Boost RSV Drug Supply -- Market Talk

25. juuli 2024, 11:23 UTC

Market Talk

Tulu

Sanofi Results Are Positive -- Market Talk

25. juuli 2024, 05:33 UTC

Tulu

Analysts Saw Sanofi 2Q Sales at EUR10.4B

25. juuli 2024, 05:33 UTC

Tulu

Sanofi 2Q Sales EUR10.745B

25. juuli 2024, 05:30 UTC

Tulu

Sanofi Had Seen 2024 Business Earnings Per Share Decreasing Low Single Digit at Constant Currency

25. juuli 2024, 05:30 UTC

Tulu

Sanofi Now Expects 2024 Business Earnings Per Share to Be Stable at Constant Currency

25. juuli 2024, 05:30 UTC

Tulu

Analysts Saw Sanofi 2Q Business Operating Income at EUR2.69B

25. juuli 2024, 05:30 UTC

Tulu

Sanofi 2Q Net Pft EUR1.11B

25. juuli 2024, 05:30 UTC

Tulu

Sanofi Raises 2024 View

25. juuli 2024, 05:30 UTC

Tulu

Sanofi 2Q Business Operating Income EUR2.81B

9. juuli 2024, 09:05 UTC

Peamised uudised

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

3. juuli 2024, 14:18 UTC

Omandamised, ülevõtmised, äriostud

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

27. juuni 2024, 10:39 UTC

Suurimad hinnamuutused turgudel

Vigil Neuroscience Shares Soar on $40M Sanofi Investment

27. juuni 2024, 06:08 UTC

Omandamised, ülevõtmised, äriostud

Vigil Neuroscience Is a Clinical-Stage Biotechnology Company >VIGL

27. juuni 2024, 06:08 UTC

Omandamised, ülevõtmised, äriostud

Vigil: Program Includes Clinical Candidate VG-3927, Being Evaluated in Phase 1 Study for Alzheimer's >VIGL

27. juuni 2024, 06:08 UTC

Omandamised, ülevõtmised, äriostud

Vigil: To Grant Sanofi Exclusive Right of First Negotiation for License of Small Molecule TREM2 Agonist Program >VIGL

27. juuni 2024, 06:07 UTC

Omandamised, ülevõtmised, äriostud

Vigil Expects Proceeds to Extend Cash Runway Into 2026 >VIGL

27. juuni 2024, 06:06 UTC

Omandamised, ülevõtmised, äriostud

Vigil: Will Use Proceeds to Fund R&D Activities >VIGL

27. juuni 2024, 06:06 UTC

Omandamised, ülevõtmised, äriostud

Vigil: Each Share Convertible Into 10 Shares of Common Stock >VIGL

27. juuni 2024, 06:06 UTC

Omandamised, ülevõtmised, äriostud

Vigil: Sanofi Will Purchase 537,634 of Company's Series A Non-Voting Preferred Shares >VIGL

30. mai 2024, 13:10 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Acquisition Relates to Human Protein to Treat Patients With Rare Hereditary Diseases

30. mai 2024, 13:08 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Completes Acquisition of Biotech Inhibrx

30. mai 2024, 13:01 UTC

Omandamised, ülevõtmised, äriostud

Press Release: Sanofi Completes Acquisition Of Inhibrx, Inc. >SAN.FR

10. mai 2024, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Inhibrx: Following Inhibrx Merger With Sanofi, Inhibrx Biosciences to Trade Under INBX

Võrdlus sarnastega

Hinnamuutus

Sanofi Prognoos

Hinnasiht

By TipRanks

0.47% tõus

12 kuu keskmine prognoos

Keskmine 58 USD 0.47%

Kõrge 60 USD

Madal 56 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Sanofi 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Sanofi aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

56.21 / 58.15Toetus ja vastupanu

The bullish and bearish events are balanced.

All events are bullish.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Sanofi

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.